BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Laburthe M, Voisin T, El Firar A. Orexins/hypocretins and orexin receptors in apoptosis: a mini-review. Acta Physiologica 2010;198:393-402. [DOI: 10.1111/j.1748-1716.2009.02035.x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 24] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Intes L, Bahut M, Nicole P, Couvineau A, Guette C, Calenda A. Intestinal cell targeting of a stable recombinant Cu–Zn SOD from Cucumis melo fused to a gliadin peptide. Journal of Biotechnology 2012;159:99-107. [DOI: 10.1016/j.jbiotec.2012.02.019] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
2 Couvineau A, Voisin T, Nicole P, Gratio V, Blais A. Orexins: A promising target to digestive cancers, inflammation, obesity and metabolism dysfunctions. World J Gastroenterol 2021; 27(44): 7582-7596 [PMID: 34908800 DOI: 10.3748/wjg.v27.i44.7582] [Reference Citation Analysis]
3 Heifetz A, Morris GB, Biggin PC, Barker O, Fryatt T, Bentley J, Hallett D, Manikowski D, Pal S, Reifegerste R, Slack M, Law R. Study of Human Orexin-1 and -2 G-Protein-Coupled Receptors with Novel and Published Antagonists by Modeling, Molecular Dynamics Simulations, and Site-Directed Mutagenesis. Biochemistry 2012;51:3178-97. [DOI: 10.1021/bi300136h] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 3.1] [Reference Citation Analysis]
4 Heifetz A, Barker O, Morris GB, Law RJ, Slack M, Biggin PC. Toward an understanding of agonist binding to human Orexin-1 and Orexin-2 receptors with G-protein-coupled receptor modeling and site-directed mutagenesis. Biochemistry 2013;52:8246-60. [PMID: 24144388 DOI: 10.1021/bi401119m] [Cited by in Crossref: 26] [Cited by in F6Publishing: 24] [Article Influence: 2.9] [Reference Citation Analysis]
5 Laburthe M, Voisin T. The orexin receptor OX(1)R in colon cancer: a promising therapeutic target and a new paradigm in G protein-coupled receptor signalling through ITIMs. Br J Pharmacol 2012;165:1678-87. [PMID: 21627633 DOI: 10.1111/j.1476-5381.2011.01510.x] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
6 Alexandre D, Hautot C, Mehio M, Jeandel L, Courel M, Voisin T, Couvineau A, Gobet F, Leprince J, Pfister C, Anouar Y, Chartrel N. The orexin type 1 receptor is overexpressed in advanced prostate cancer with a neuroendocrine differentiation, and mediates apoptosis. Eur J Cancer 2014;50:2126-33. [PMID: 24910418 DOI: 10.1016/j.ejca.2014.05.008] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.0] [Reference Citation Analysis]
7 Blais A, Drouin G, Chaumontet C, Voisin T, Couvelard A, Even PC, Couvineau A. Impact of Orexin-A Treatment on Food Intake, Energy Metabolism and Body Weight in Mice. PLoS One 2017;12:e0169908. [PMID: 28085909 DOI: 10.1371/journal.pone.0169908] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 3.2] [Reference Citation Analysis]
8 Dayot S, Speisky D, Couvelard A, Bourgoin P, Gratio V, Cros J, Rebours V, Sauvanet A, Bedossa P, Paradis V, Ruszniewski P, Couvineau A, Voisin T. In vitro, in vivo and ex vivo demonstration of the antitumoral role of hypocretin-1/orexin-A and almorexant in pancreatic ductal adenocarcinoma. Oncotarget 2018;9:6952-67. [PMID: 29467942 DOI: 10.18632/oncotarget.24084] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 2.0] [Reference Citation Analysis]
9 Subramanian S, Ravichandran M. Orexin receptors: Targets and applications. Fundam Clin Pharmacol 2021. [PMID: 34464995 DOI: 10.1111/fcp.12723] [Reference Citation Analysis]
10 Xu T, Yang Y, Ward R, Gao L, Liu Y. Orexin receptors: Multi-functional therapeutic targets for sleeping disorders, eating disorders, drug addiction, cancers and other physiological disorders. Cellular Signalling 2013;25:2413-23. [DOI: 10.1016/j.cellsig.2013.07.025] [Cited by in Crossref: 68] [Cited by in F6Publishing: 65] [Article Influence: 7.6] [Reference Citation Analysis]
11 Taximaimaiti R, Abuliken X, Maihemuti M, Abudujilile D, Abudulimu H. Elevated Expression of Ox2R in Cervical Cancers and Placentas of Uyghur Women in Xinjiang, China. Asian Pac J Cancer Prev 2016;17:4959-63. [PMID: 28032723 DOI: 10.22034/APJCP.2016.17.11.4959] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Nicole P, Couvineau P, Jamin N, Voisin T, Couvineau A. Crucial role of the orexin-B C-terminus in the induction of OX1 receptor-mediated apoptosis: analysis by alanine scanning, molecular modelling and site-directed mutagenesis. Br J Pharmacol 2015;172:5211-23. [PMID: 26282891 DOI: 10.1111/bph.13287] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
13 Kong T, Qiu K, Liu M, Cheng B, Pan Y, Yang C, Chen J, Wang C. Orexin-A protects against oxygen-glucose deprivation/reoxygenation-induced cell damage by inhibiting endoplasmic reticulum stress-mediated apoptosis via the Gi and PI3K signaling pathways. Cellular Signalling 2019;62:109348. [DOI: 10.1016/j.cellsig.2019.109348] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 2.3] [Reference Citation Analysis]
14 Xu TR, Ward RJ, Pediani JD, Milligan G. Intramolecular fluorescence resonance energy transfer (FRET) sensors of the orexin OX1 and OX2 receptors identify slow kinetics of agonist activation. J Biol Chem 2012;287:14937-49. [PMID: 22389503 DOI: 10.1074/jbc.M111.334300] [Cited by in Crossref: 17] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
15 Alain C, Pascal N, Valérie G, Thierry V. Orexins/Hypocretins and Cancer: A Neuropeptide as Emerging Target. Molecules 2021;26:4849. [PMID: 34443437 DOI: 10.3390/molecules26164849] [Reference Citation Analysis]
16 Ragionieri L, Ravanetti F, Di Lecce R, Botti M, Ciccimarra R, Bussolati S, Basini G, Gazza F, Cacchioli A. Immunolocalization of Orexin A and its receptors in the different structures of the porcine ovary. Ann Anat 2018;218:214-26. [PMID: 29738835 DOI: 10.1016/j.aanat.2018.04.006] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
17 Biegańska K, Sokołowska P, Jöhren O, Zawilska JB. Orexin A suppresses the growth of rat C6 glioma cells via a caspase-dependent mechanism. J Mol Neurosci 2012;48:706-12. [PMID: 22588980 DOI: 10.1007/s12031-012-9799-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 2.1] [Reference Citation Analysis]
18 Li M, Meng Y, Chu B, Shen Y, Xue X, Song C, Liu X, Ding M, Cao X, Wang P, Xu S, Bi J, Xie Z. Orexin-A exacerbates Alzheimer's disease by inducing mitochondrial impairment. Neurosci Lett 2020;718:134741. [PMID: 31927055 DOI: 10.1016/j.neulet.2020.134741] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
19 Messal N, Fernandez N, Dayot S, Gratio V, Nicole P, Prochasson C, Chantret I, LeGuilloux G, Jarry A, Couvelard A, Tréton X, Voisin T, Ogier-Denis E, Couvineau A. Ectopic expression of OX1R in ulcerative colitis mediates anti-inflammatory effect of orexin-A. Biochim Biophys Acta Mol Basis Dis 2018;1864:3618-28. [PMID: 30251681 DOI: 10.1016/j.bbadis.2018.08.023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
20 Adeghate E, Fernandez-Cabezudo M, Hameed R, El-Hasasna H, El Wasila M, Abbas T, Al-Ramadi B. Orexin-1 receptor co-localizes with pancreatic hormones in islet cells and modulates the outcome of streptozotocin-induced diabetes mellitus. PLoS One 2010;5:e8587. [PMID: 20062799 DOI: 10.1371/journal.pone.0008587] [Cited by in Crossref: 16] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
21 Xu D, Kong T, Shao Z, Liu M, Zhang R, Zhang S, Kong Q, Chen J, Cheng B, Wang C. Orexin-A alleviates astrocytic apoptosis and inflammation via inhibiting OX1R-mediated NF-κB and MAPK signaling pathways in cerebral ischemia/reperfusion injury. Biochim Biophys Acta Mol Basis Dis 2021;1867:166230. [PMID: 34358627 DOI: 10.1016/j.bbadis.2021.166230] [Reference Citation Analysis]
22 Chase MH. A unified survival theory of the functioning of the hypocretinergic system. J Appl Physiol (1985) 2013;115:954-71. [PMID: 23640599 DOI: 10.1152/japplphysiol.00700.2012] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.1] [Reference Citation Analysis]
23 Dehan P, Canon C, Trooskens G, Rehli M, Munaut C, Van Criekinge W, Delvenne P. Expression of Type 2 Orexin Receptor in Human Endometrium and Its Epigenetic Silencing in Endometrial Cancer. The Journal of Clinical Endocrinology & Metabolism 2013;98:1549-57. [DOI: 10.1210/jc.2012-3263] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
24 Couvineau A, Dayot S, Nicole P, Gratio V, Rebours V, Couvelard A, Voisin T. The Anti-tumoral Properties of Orexin/Hypocretin Hypothalamic Neuropeptides: An Unexpected Therapeutic Role. Front Endocrinol (Lausanne) 2018;9:573. [PMID: 30319552 DOI: 10.3389/fendo.2018.00573] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]